Once I saw the Steel Partners control, I'd seen enough.
I haven't looked at the terms of the preferred conversions.
My fear is it wouldn't matter to the minority holders. Even if there's more cash on the BS, does that equate to value available to common holders? Or could Lichtenstein delist the company and use it as a private NOL farm while the poison pill prevents any outside offers from being a threat and the common languishes in OTC land? "Expert Market," anyone?
Maybe not but I'd rather avoid companies with proven shysters at the helm.